Loading
Life sciences · Journal article
Biomedicines · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the treatment of type 2 diabetes mellitus and obesity through potent metabolic and cardiometabolic effects. Beyond glucose regulation, accumulating evidence indicates that GLP-1 signalling exerts pleiotropic actions on intestinal physiology, epithelial barrier integrity, mucosal immunity and host–microbiota interactions, suggesting a potential therapeutic role in inflammatory bowel disease (IBD). Concurrently, the increasing prevalence of obesity and metabolic dysfunction among patients with IBD has highlighted the need for therapeutic approaches that address both intestinal inflammation and its metabolic determinants. This review summarizes the physiological functions of GLP-1 and critically evaluates the molecular, experimental and clinical evidence concerning GLP-1 receptor agonists in IBD. Particular emphasis is placed on epithelial barrier function, innate and adaptive immunity, inflammatory signalling, intestinal permeability and gut microbial homeostasis. Experimental studies generally support anti-inflammatory and mucosal-protective effects in preclinical models, whereas emerging clinical evidence indicates substantial metabolic efficacy and generally reassuring short-term safety. A central concept of this review is the gut–immune–metabolic axis, integrating endocrine signalling, epithelial function, mucosal immunity, gut microbiota and systemic metabolism. Nevertheless, adequately powered prospective randomized controlled trials with objective inflammatory, endoscopic and histological endpoints are required before GLP-1RAs can be considered disease-modifying therapies in IBD.